✦ LIBER ✦

Early Development of Castrate Resistance Varies with Different Dosing Regimens of Luteinizing Hormone Releasing Hormone Agonist in Primary Hormonal Therapy for Prostate Cancer

✍ Scribed by Jeremy M. Blumberg; Eric O. Kwon; T. Craig Cheetham; Fang Niu; Charles E. Shapiro; Judith Pacificar; Ronald K. Loo; Stephen G. Williams; Gary W. Chien

Book ID: 116953157
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 132 KB
Volume: 77
Category: Article
ISSN: 0090-4295
DOI: 10.1016/j.urology.2010.08.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TREATMENT FAILURE IS ASSOCIATED WITH DIF

TREATMENT FAILURE IS ASSOCIATED WITH DIFFERENT DOSING REGIMENS OF LEUTINIZING HORMONE RELEASING HORMONE AGONIST THERAPY FOR PROSTATE CANCER

✍ Blumberg, Jeremy M; Kwon, Eric; Cheetham, T. Craig; Niu, Fang; Jacobsen, Steven 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 56 KB

Chemohormonal therapy as primary treatme

Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist

✍ MASANORI NOGUCHI; SHINSHI NODA; MASAKI YOSHIDA; SHOICHI UEDA; TAIZO SHIRAISHI; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Luteinizing hormone-releasing hormone ag

Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol

✍ Nicholas Bruchovsky; S. Larry Goldenberg; Koichiro Akakura; Paul S. Rennie 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

Risedronate prevents early bone loss and

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

✍ Pamela Taxel; Robert Dowsett; Lee Richter; Pamela Fall; Alison Klepinger; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

862 RISEDRONATE PREVENTS EARLY BONE LOSS

862 RISEDRONATE PREVENTS EARLY BONE LOSS AND INCREASED BONE TURNOVER IN THE FIRST 6 MONTHS OF LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY FOR PROSTATE CANCER

✍ Taxel, Pamela; Dowsett, Robert; Richter, Lee; Fall, Pamela; Kleppinger, Alison; 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 94 KB

Down-staging of early stage prostate can

Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist

✍ Fernand Labrie; Lionel Cusan; José-Luis Gomez; Pierre Diamond; Raul Suburu; Mart 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 885 KB